CD79A and COVID-19: With the exception of a few preliminary case series and reports, characterized by relatively limited sample sizes [11], [12], [13], most studies that have explored, deciphered and monitored the immune response developed after COVID-19 vaccination have almost solely focused on assaying serum IgG antibodies and systemic cell-mediated immunity [14], thus discounting the potential role that neutralizing IgA antibodies would play in limiting viral spread in the community and thereby facilitating the achievement of herd immunity.